What is Cytena?
Cytena operates at the intersection of biotechnology and advanced engineering, providing automated workflows that are essential for the modern development of therapeutic antibodies, viral vectors, and cell therapies. As a subsidiary of BICO, the company leverages the broader bioconvergence paradigm to integrate hardware and software, effectively streamlining the creation of stable cell lines. Their core product suite, which includes high-precision single-cell dispensers, addresses the critical industry need for faster, safer, and more cost-effective laboratory automation. By serving a diverse clientele ranging from boutique biotech firms to large-scale contract development and manufacturing organizations (CDMOs), Cytena has established itself as an indispensable infrastructure provider in the global drug discovery pipeline.
How much funding has Cytena raised?
Cytena has raised a total of $3.6M across 2 funding rounds:
Angel/Seed
$1.2M
Series A
$2.4M
Angel/Seed (2015): $1.2M with participation from High-Tech Gru00fcnderfonds
Series A (2019): $2.4M, investors not publicly disclosed
Key Investors in Cytena
High-Tech Gru00fcnderfonds
A prominent German venture capital firm that specializes in providing seed-stage financing to high-potential technology startups across various industrial sectors.
Undisclosed Investor
An institutional partner participating in the latest strategic financing round to support the company's enterprise-level expansion.
What's next for Cytena?
With the recent influx of capital, Cytena is well-positioned to accelerate its R&D initiatives and expand its footprint in the competitive landscape of lab automation. The strategic focus will likely shift toward enhancing the throughput of their automated platforms and deepening their integration within the BICO ecosystem to offer comprehensive bioconvergence solutions. As the demand for personalized medicine and complex biologics continues to rise, Cytena's ability to modernize cell line development will be a key driver of its long-term growth. Future milestones will likely involve scaling manufacturing capabilities to meet the increasing global demand for high-efficiency bioprocessing tools, ensuring that the company remains at the forefront of the digital transformation in life sciences.
See full Cytena company page
